Skip to content

Questions That Vertex Pharmaceuticals Need To Answer About The Test Results For The Combination Of Orphan Drug Kalydeco (Ivacaftor) And VX-809: Perspective

October 10, 2012

      There is great anticipation about the presentation scheduled for this Thursday, 10/11/12 at 11:40 AM EDT at the North American Cystic Fibrosis (NACF) conference, for the final data of the Phase II Study of Kalydeco in combination with VX-809 for Cystic Fibrosis (CF).’s October 9, 2012 article presents 5 questions that Deutsche Bank Securities biotech analyst Robyn Karnauskas says that Vertex Pharmaceuticals need to answer to boost investor confidence.

Copyright © 2012-2013, Ann-Teresa Cusenza and Orphan Druganaut Blog.  All rights reserved.

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: